By giving an overview about existing studies on this topic, we hope to provide insights into optimizing therapeutic strategies for patients with HER2-positive breast cancer brain metastases (BCBM) and show implications for future clinical use and directions for research on radionecrosis and HER2-targeted therapies. Here, ERBB2 is linked to breast carcinoma.